An ageing biomarker signature predicts chronic disease cluster trajectories, physical function and mortality: validation in the TILDA and HRS cohorts
An 18-marker blood test identifies older adults at highest risk for multiple diseases and decline, validated across two countries and potentially guiding preventive care.
This binational longitudinal study validates an 18-marker blood biomarker signature that identifies a high-risk aging subpopulation with significantly elevated risk of multimorbidity, frailty, functional decline, and death across 12-year follow-up. Cross-national validation in both Irish (TILDA) and US (HRS) cohorts strengthens the case for routine biomarker-based aging risk stratification to guide preventive interventions.
What the study was
- Study design
- Prospective longitudinal cohort study with external validation
- Population
- Community-dwelling adults aged 50+ from Ireland (TILDA, n=4,961) and USA (HRS, n=3,914)
- Sample size
- 8875
- Category
- Prevention
- Maturity
- Validated
- Journal
- Age and Ageing
Why it surfaced
Large cross-national cohort (n=8,875 total) with 12-year follow-up; validated in two independent populations; 18 standard blood biomarkers are clinically accessible; Age and Ageing is the premier geriatrics journal.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.